• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?

    Simply Wall St·11/05/2026 13:27:45
    Listen to the news
    • Twist Bioscience recently introduced Twist MRD Express and Twist Express Screening Antibodies, expanding its synthetic DNA and protein tools for cancer research and antibody discovery with rapid, high throughput custom production.
    • The new offerings aim to shorten development timelines for liquid biopsy, MRD assays and antibody screening, which could influence demand patterns, capacity use and future product mix across Twist Bioscience’s broader portfolio.
    • We will look at how Twist Bioscience's investment narrative is shaped by Twist MRD Express and its focus on faster personalized oncology tools.

    Scan other cancer research suppliers moving quickly on high throughput tools by checking out the 38 healthcare AI stocks alongside Twist Bioscience’s latest MRD and antibody launches.

    Twist Bioscience Investment Narrative Recap

    To own Twist Bioscience, you need to believe its high-throughput DNA and protein platform can turn strong product interest into a larger, more diverse customer base while gradually shrinking operating losses. The recent MRD Express and antibody launches support that thesis on paper, but the immediate impact on revenue mix and margins is hard to quantify in the near term.

    The key near term catalyst remains Twist Bioscience’s push toward adjusted EBITDA breakeven, helped by gross margins already above 50%. The biggest risk stays the same. The firm is still loss making, with heavy reliance on a small pool of large NGS customers and a share price that has already moved sharply.

    The Twist MRD Express launch is the clearest operational tie to those catalysts. It leans on the existing silicon DNA platform, offering up to 10,000 custom probes, rapid turnaround and design support. That kind of scale can matter if liquid biopsy and MRD researchers standardize on Twist workflows for recurrent testing.

    This product also sits squarely against current risks. Execution missteps could limit adoption, which matters when revenue concentration is high and the stock trades on a rich P/S multiple. For you as a shareholder, the central question is whether MRD Express can help Twist Bioscience convert new assays into durable, higher margin demand without needing fresh capital.

    Twist Bioscience is tied to a consensus narrative that points to US$746.7 million in revenue and US$118.8 million in earnings by 2029, built on analyst assumptions of 20.0% yearly revenue growth and a swing in earnings of about US$255.5 million from a loss of US$136.7 million today.

    Uncover why Twist Bioscience's fair value indicates an 18% potential upside to its current price that could narrow quickly.

    NasdaqGS:TWST 1-Year Stock Price Chart
    NasdaqGS:TWST 1-Year Stock Price Chart

    Exploring Other Perspectives

    One of the biggest swing factors in the alternate Twist Bioscience story is how far AI driven demand could stretch future capacity. The most optimistic analysts were already modeling revenue of about US$840.7 million and earnings of US$31.6 million by 2029 before MRD Express arrived. That is a very different script from consensus, so treat this launch as a prompt to compare those scenarios yourself.

    Explore 3 other Twist Bioscience fair value estimates, including one that suggests potential upside of up to 135% from the current price.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

    Looking For More Investment Ideas Beyond Twist Bioscience?

    If Twist Bioscience has you thinking about where asymmetric opportunities might sit next, it can help to line it up against a broader watchlist. The Simply Wall St Screener lets you filter by balance sheet strength, income potential or valuation so you can build a set of candidates that actually fits your risk tolerance.